OBJECTIVES: Candida species are major causes of invasive mycoses in immunocompetent and immunocompromised hosts. Treatment options are limited in the setting of antifungal resistance and increased rates of echinocandin-resistant Candida glabrata have been reported. The novel arylamidine T-2307 demonstrates potent in vitro antifungal activity against Candida species. Our objective was to evaluate the in vitro and in vivo activity of T-2307 against resistant C. glabrata. METHODS: In vitro activity was determined against 42 clinical C. glabrata isolates, including 17 echinocandin-resistant strains. Neutropenic ICR mice were inoculated intravenously with an echinocandin-resistant C. glabrata isolate (T-2307; caspofungin MICs ≤0.008 and 0.5 mg/L, respectively). Therapy with vehicle control, T-2307 (0.75, 1.5, 3 or 6 mg/kg subcutaneously once daily) or caspofungin (1 or 10 mg/kg intraperitoneally once daily) began 1 day post-challenge. Kidneys were collected on day 8 and fungal burden was assessed by counting cfu. RESULTS: T-2307 demonstrated potent in vitro activity against C. glabrata (geometric mean MIC 0.0135 mg/L), which was maintained against echinocandin-resistant isolates (geometric mean MIC 0.0083 mg/L). T-2307 also demonstrated in vivo efficacy in mice infected with echinocandin-resistant C. glabrata. Significant reductions in fungal burden were observed at each dosage level of T-2307 compared with control. Reductions in fungal burden were also observed with high-dose caspofungin. CONCLUSIONS: T-2307 demonstrated potent in vitro activity against C. glabrata, including echinocandin-resistant isolates, which translated into in vivo efficacy against invasive candidiasis caused by an echinocandin-resistant C. glabrata strain. These results demonstrate the potential for T-2307 as therapy against echinocandin-resistant Candida.
OBJECTIVES:Candida species are major causes of invasive mycoses in immunocompetent and immunocompromised hosts. Treatment options are limited in the setting of antifungal resistance and increased rates of echinocandin-resistant Candida glabrata have been reported. The novel arylamidineT-2307 demonstrates potent in vitro antifungal activity against Candida species. Our objective was to evaluate the in vitro and in vivo activity of T-2307 against resistant C. glabrata. METHODS: In vitro activity was determined against 42 clinical C. glabrata isolates, including 17 echinocandin-resistant strains. Neutropenic ICR mice were inoculated intravenously with an echinocandin-resistant C. glabrata isolate (T-2307; caspofungin MICs ≤0.008 and 0.5 mg/L, respectively). Therapy with vehicle control, T-2307 (0.75, 1.5, 3 or 6 mg/kg subcutaneously once daily) or caspofungin (1 or 10 mg/kg intraperitoneally once daily) began 1 day post-challenge. Kidneys were collected on day 8 and fungal burden was assessed by counting cfu. RESULTS:T-2307 demonstrated potent in vitro activity against C. glabrata (geometric mean MIC 0.0135 mg/L), which was maintained against echinocandin-resistant isolates (geometric mean MIC 0.0083 mg/L). T-2307 also demonstrated in vivo efficacy in mice infected with echinocandin-resistant C. glabrata. Significant reductions in fungal burden were observed at each dosage level of T-2307 compared with control. Reductions in fungal burden were also observed with high-dose caspofungin. CONCLUSIONS:T-2307 demonstrated potent in vitro activity against C. glabrata, including echinocandin-resistant isolates, which translated into in vivo efficacy against invasive candidiasis caused by an echinocandin-resistant C. glabrata strain. These results demonstrate the potential for T-2307 as therapy against echinocandin-resistant Candida.
Authors: Nathan P Wiederhold; Laura K Najvar; Annette W Fothergill; Rosie Bocanegra; Marcos Olivo; Dora I McCarthy; William R Kirkpatrick; Yoshiko Fukuda; Junichi Mitsuyama; Thomas F Patterson Journal: Antimicrob Agents Chemother Date: 2014-12-01 Impact factor: 5.191
Authors: Nathan P Wiederhold; Laura K Najvar; Rosie Bocanegra; Destiny Molina; Marcos Olivo; John R Graybill Journal: Antimicrob Agents Chemother Date: 2007-02-16 Impact factor: 5.191
Authors: Barbara D Alexander; Melissa D Johnson; Christopher D Pfeiffer; Cristina Jiménez-Ortigosa; Jelena Catania; Rachel Booker; Mariana Castanheira; Shawn A Messer; David S Perlin; Michael A Pfaller Journal: Clin Infect Dis Date: 2013-03-13 Impact factor: 9.079
Authors: Nicholas D Beyda; Julie John; Abdullah Kilic; Mohammad J Alam; Todd M Lasco; Kevin W Garey Journal: Clin Infect Dis Date: 2014-05-30 Impact factor: 9.079
Authors: Cau D Pham; Naureen Iqbal; Carol B Bolden; Randall J Kuykendall; Lee H Harrison; Monica M Farley; William Schaffner; Zintars G Beldavs; Tom M Chiller; Benjamin J Park; Angela A Cleveland; Shawn R Lockhart Journal: Antimicrob Agents Chemother Date: 2014-06-02 Impact factor: 5.191
Authors: Peter G Pappas; Carol A Kauffman; David Andes; Daniel K Benjamin; Thierry F Calandra; John E Edwards; Scott G Filler; John F Fisher; Bart-Jan Kullberg; Luis Ostrosky-Zeichner; Annette C Reboli; John H Rex; Thomas J Walsh; Jack D Sobel Journal: Clin Infect Dis Date: 2009-03-01 Impact factor: 9.079
Authors: Michael A Pfaller; David R Andes; Daniel J Diekema; David L Horn; Annette C Reboli; Coleman Rotstein; Billy Franks; Nkechi E Azie Journal: PLoS One Date: 2014-07-03 Impact factor: 3.240
Authors: Nathan P Wiederhold; Laura K Najvar; Rosie Jaramillo; Marcos Olivo; Jason Pizzini; Gabriel Catano; Thomas F Patterson Journal: J Antimicrob Chemother Date: 2018-02-01 Impact factor: 5.790
Authors: Nathan P Wiederhold; Laura K Najvar; Rosie Jaramillo; Marcos Olivo; Hoja Patterson; April Connell; Yoshiko Fukuda; Junichi Mitsuyama; Gabriel Catano; Thomas F Patterson Journal: Antimicrob Agents Chemother Date: 2020-02-21 Impact factor: 5.191